



SINCLAIR PHARMA PLC

EXPANSION OF ALOCLAIR® DISTRIBUTION IN EU AND FIRST DISTRIBUTION AGREEMENT FOR ATOPICLAIR™ IN EU

Godalming UK, 17 February 2005: Sinclair Pharma plc ("Sinclair" or the "Company") (SPH.L), the specialty pharmaceutical company, announces today that it has reached agreement with Sunstar Suisse SA ("Sunstar"), part of the Sunstar Group, to substantially expand its European agreement for the distribution of Aloclair® Rinse and Aloclair® Gel, a treatment for mouth ulcers, to add eight new European countries. Sunstar has also licensed Aloclair® Spray in all 20 European countries where it sells or will sell the Rinse and Gel.

The global mouth ulcers market is estimated to be worth more than \$1 billion per annum. TNS market research conducted for Sinclair indicates that 16% of the adult population get an oral ulcer over a 12 month period and 64% of that population seek pain relief with a medication. That research translates to a user base of over 100 million adults in the EU and US.

Sinclair also announces today that it has licensed Atopiclair™ in Portugal to Dysonovis, a young and growing company with a sales force that addresses dermatologists, GP's, pediatricians and pharmacies. Atopiclair™ is Sinclair's non-steroidal cream indicated for relief and management of the itching, burning and pain that patients experience with atopic dermatitis and allergic contact dermatitis (skin allergy). Atopiclair™ was recently licensed in the US to Chester Valley Pharmaceuticals, a US company focused on the dermatology market. Atopiclair™ is the first prescription medical device in the US authorised by the US FDA to relieve the symptoms of atopic dermatitis and allergic contact dermatitis.

All three Aloclair® products (an oral rinse solution, an oral gel and the oral spray) will now be distributed by Sunstar in France, Germany, Austria, Spain, Sweden, Denmark, Portugal, Holland, Belgium, Greece, Cyprus, Luxembourg. Sunstar has today added the Czech Republic, Iceland, Switzerland, Slovakia, Slovenia, Croatia, Bosnia and Serbia to the list of countries distributing Aloclair®. Aloclair®'s three delivery systems are approved in the US and the EU.

Dr. Michael Flynn, Chief Executive of Sinclair, commented: "Through this agreement we have significantly increased the European marketing and distribution network for Aloclair® in Europe as well as agreeing the introduction of the Aloclair® Spray line extension in 20 countries. Aloclair® is presently our largest product and these agreements represent important steps towards establishing Aloclair® as a successful global brand.

"We are also very engaged in the establishment of a sound marketing and distribution network for Atopiclair™ in Europe this year and the agreement with Dysonovis in Portugal represents the first, albeit small, step towards achieving this goal."



For further enquiries:

Sinclair Pharma plc

Dr Michael Flynn, CEO

John Barrington-Carver (Media Enquiries)

Tel: (0)1483 426 644

Tel: (0) 7831 655 630

Financial Dynamics

Ben Atwell / Lucy Briggs

Tel: (0) 207 831 3113

Notes to editors:

Sinclair Pharma plc

Sinclair Pharma plc based in Godalming in the UK, is quoted on the Alternative Investment Market (AIM) on the London Stock Exchange and has focused on the acquisition and development of niche patented pharmaceutical products in the fields of oral health, oncology support and dermatology, and bringing them to the international market place via out-licensing partners. The Company combines product evaluation, product development, regulatory and business development expertise to add value to its acquired and in-house developed products. A key element of the Sinclair business model is to minimise risk and exposure by avoiding involvement in lengthy R&D programmes and rapidly achieving global distribution through a network of marketing partners. The Company has already licensed its products for distribution in over 40 countries around the world. www.sinclairpharma.com

Sunstar Suisse

Sunstar Suisse is part of the international Sunstar Group with sales of 62.35 Billion Yen (US\$590 Million) in the year ended 31 March 2004. The Group employs 1490 people worldwide including 600 at Sunstar Butler. Sunstar designs, manufactures, and sells oral care products used in the prevention of tooth decay and periodontal disease. The Company's principal products include toothbrushes, interdental cleaners, and other preventive aids. In the United States and Canada, Sunstar Butler sells products to dental professionals who sell or dispense it to patients, or use it during treatment. In addition, Sunstar Butler sells products to consumer retail market stores. www.sunstar.com

"Safe Harbor" Statement under the US Private Securities Litigation Reform Act of 1995: Some or all of the statements in this document that relate to future plans, expectations, events, performances and the like are forward-looking statements, as defined in the US Private Securities Litigation Reform Act of 1995. Actual results of events could differ materially from those described in the forward-looking statements due to a variety of factors.